ArticleNPJ Parkinson's disease2025
Modulatory effect of levodopa on the basal ganglia-cerebellum connectivity in Parkinson's disease.
Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cerebrospinal fluid dopamine 3-O-sulfate as a novel biomarker for predicting motor complications in Parkinson's disease: insights from the PPMI cohort.Journal of translational medicine · 2026Article
- Solute carrier protein family: physiological functions, disease associations, and therapeutic potential in immune-related disorders.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term levodopa use in Parkinson's disease is associated with declining efficacy and motor complications. Understanding its effects on brain reorganisation is vital for optimizing therapy. Using data from Parkinson's Progression Marker Initiative, we investigated levodopa's impact on resting-state functional connectivity within the cortico-basal ganglia-cerebellum system in 29 patients, under drug-naïve and levodopa-medicated conditions. Univariate comparisons of inter-regional connectivity between conditions were conducted, and multivariate combinations of connections within and between networks were assessed. No significant effect of levodopa was found using the univariate seed-based approach. However, the network connectivity pattern between basal ganglia and cerebellum showed robust classification power. Eigenvector Centrality Mapping (ECM) further identified functional hubs, with cerebellar hubs being the only ones within the cortico-basal ganglia-cerebellum system affected by medication. Our study provides further insight into the importance of inter-network functional connectivity in Parkinson's and the impact of levodopa medication, highlighting the often-overlooked role of the cerebellum.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.